Evidence map›Paper›PMID 32595497›Full record

ArticleFrontiers in pharmacology2020

Exploring the Regulation Mechanism of Xihuang Pill,

Kailin Yang, Liuting Zeng, Anqi Ge, Tingting Bao, Tao Xu, Xiaobing Xie, Lifang Liu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Exploring the Effect of Jiawei Buguzhi Pills on TGF-Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kailin YangGalactophore Department, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.
Liuting ZengGraduate College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Anqi GeGalactophore Department, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.
Tingting BaoDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Tao XuGalactophore Department, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.
Xiaobing XieGalactophore Department, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.
Lifang LiuGalactophore Department, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.
First Affiliated Hospital of Hunan University of Traditional Chinese Medicine · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundXihuang Pill (XHP) is mainly used to treat "Ru Yan (breast cancer)". Evidence-based medical evidence and showed that XHP improves the efficacy of chemotherapy and reduced chemotherapy-induced toxicity in breast cancer patients. However, the mechanism of XHP against breast cancer is not clear.

methodsThe effect of XHP extract on cell half-inhibitory concentration (IC50) and cell viability of MD-MB-231 cells was detected by CCK-8 method. The cell inhibition rate of MDA-MB-453 cells were detected by MTT method. Apoptosis was detected by flow cytometry, cell transfer ability was detected by Transwell method, and cell proliferation ability was detected by colony formation assay. The expression of Notch1, β-catenin and c-myc mRNA in MDA-MB-453 cells were detected by real-time fluorescence quantitative PCR. Then, chemical informatics and transcriptomics methodology was utilized to predict the potential compounds and targets of XHP, and collect triple negative breast cancer (TNBC) genes and the data of

resultsThe IC50 was 15.08 g/L (for MD-MB-231 cells). After interfering with MD-MB-231 cells with 15.08 g/L XHP extract for 72 h, compared with the control group, the cell viability, migration and proliferation was significantly decreased, while early apoptosis and late apoptosis were significantly increased (P < 0.01). After interfering with MDA-MB-453 cells with 6 g/L XHP extract for 72 h, compared with the control group, the cell inhibition and apoptosis rate increased, while the expression of Notch1, β-catenin and c-myc mRNA decreased. (P < 0.05). The chemical informatics and transcriptomics analysis showed that four networks were constructed and analyzed: (1) potential compounds-potential targets network of XHP; (2) XHP-TNBC PPI network; (3) DEGs PPI network of

conclusionXHP may exert anti-TNBC effects through regulating biological processes, signaling pathways, targets found in this study.

Indexed as

bioinformaticschemical informaticsChinese medicinehigh-throughput omicsMDA-MB-231 celltranscriptomicstriple negative breast cancerXihuang Pill

Identifiers

PMID32595497
PMCPMC7300251
OpenAlexW3034181846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.